0000950170-23-039035.txt : 20230807 0000950170-23-039035.hdr.sgml : 20230807 20230807160212 ACCESSION NUMBER: 0000950170-23-039035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230807 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axsome Therapeutics, Inc. CENTRAL INDEX KEY: 0001579428 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454241907 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37635 FILM NUMBER: 231147497 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: (212) 332-3241 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 8-K 1 axsm-20230807.htm 8-K 8-K
0001579428false00015794282023-08-072023-08-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2023

 

 

Axsome Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37635

45-4241907

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One World Trade Center, 22nd Floor

 

New York, New York

 

10007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (212) 332-3241

 

Axsome Therapeutics, Inc.

22 Cortlandt Street, 16th Floor

New York, New York 10007

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

 

AXSM

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2023, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2023 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

Description

99.1

Press Release dated August 7, 2023.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Axsome Therapeutics, Inc.

 

 

 

 

Date:

August 7, 2023

By:

/s/ Herriot Tabuteau, M.D.

 

 

Name:

Title:

Herriot Tabuteau, M.D.
President and Chief Executive Officer

 

 EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img36028404_0.jpg 

 

 

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Total 2Q 2023 product revenue of $46.7 million

Auvelity® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth

Sunosi® 2Q 2023 net product revenue of $19.1 million

Pro forma second quarter cash balance of $468.8 million

FOCUS Phase 3 trial of solriamfetol in attention-deficit hyperactivity disorder initiated

Positive FDA pre-IND meeting feedback received for two new potential indications for solriamfetol: Phase 3 trial initiations planned for binge eating disorder in 4Q 2023, and shift work disorder in 1Q 2024

Company to host conference call today at 8:00 AM Eastern

NEW YORK, August 7, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2023.

“We exhibited strong financial performance and pipeline advancement in the second quarter. Given the positive reception to date from clinicians to the Auvelity launch, we are expanding the Auvelity sales force by approximately 100 representatives. The expansion combined with our innovative DCC approach is expected to significantly increase our reach from approximately 26,000 to 44,000 physicians who write greater than 80% of branded antidepressant prescriptions,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Our Q2 relaunch of Sunosi is also well underway, and we are seeing positive results from these efforts. Our late-stage CNS pipeline continues to expand, and we are pleased to announce the launch of three new high value potential indications for solriamfetol: ADHD, for which we recently initiated the FOCUS Phase 3 trial, and binge eating disorder and shift work disorder for which we intend to initiate Phase 3 trials over the next two quarters based on positive FDA feedback on their development plans. We also look forward to topline results from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy and the ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation, which remain on track. Following our recent public offering of common stock, we are solidly positioned to further build value across our commercial and development portfolio.”

Second Quarter 2023 Financial Highlights

•
Total product revenue for the second quarter of 2023 was $46.7 million, consisting of net product sales of $46.0 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $8.8 million.
•
Auvelity® net product sales were $27.6 million for the second quarter of 2023, representing a 76% sequential increase versus the first quarter of 2023. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022.
•
Sunosi® net product revenue was $19.1 million for the second quarter of 2023, consisting of $18.4 million in net product sales and $0.7 million in royalty revenue associated with Sunosi sales in out-licensed territories. Sunosi revenue to Axsome for the comparable period in 2022 was $8.8 million.
•
Total cost of revenue was $4.6 million for the second quarter of 2023. Total cost of revenue for the comparable period in 2022 was $1.0 million.

1

 

 

•
Research and development (R&D) expenses were $20.6 million for the second quarter of 2023, compared to $15.8 million for the comparable period in 2022. The increase was primarily related to the initiation of the FOCUS trial of solriamfetol in ADHD, the advancement of ongoing trials of AXS-05 and AXS-12, post-marketing commitments for Auvelity and Sunosi, and higher personnel costs, including non-cash stock-based compensation.
•
Selling, general, and administrative (SG&A) expenses were $78.9 million for the second quarter of 2023, compared to $31.2 million for the comparable period in 2022. The increase was primarily related to the commercialization of Auvelity and Sunosi, and higher personnel costs related to organizational growth, including non-cash stock-based compensation.
•
Net loss for the second quarter of 2023 was $67.2 million or $(1.54) per share, compared to a net loss of $41.4 million, or $(1.06) per share, for the comparable period in 2022. The net loss in the second quarter of 2023 reflects $23.6 million in non-cash charges, comprised of $15.9 million of non-cash stock-based compensation expense, $6.1 million of non-cash loss in fair value of contingent consideration, and $1.6 million of non-cash intangible asset amortization.
•
In June 2023, Axsome completed an underwritten public offering of common stock resulting in gross proceeds of $225 million. Subsequently, in July 2023, the underwriters exercised their option to purchase an additional 15% of common stock in connection with the public offering (the “green shoe”), resulting in additional gross proceeds to Axsome of $33.8 million.
•
Cash and cash equivalents totaled $437.1 million at June 30, 2023, compared to $200.8 million at December 31, 2022. The cash balance includes net proceeds from the June 2023 common stock offering and does not reflect the subsequent green shoe exercise. Pro forma cash at June 30, 2023, inclusive of net proceeds from the green shoe, totaled $468.8 million.
•
Shares of common stock outstanding were 46,726,794 at June 30, 2023.

Financial Guidance

•
Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

Commercial Highlights

Auvelity

•
Approximately 53,000 prescriptions were reported for Auvelity in the second quarter of 2023, representing a 72% sequential increase versus the first quarter of 2023.
•
Based on the initial positive market reception to the Auvelity launch, Axsome is expanding the Auvelity sales force from 162 to 260 representatives. The expansion will allow for greater reach and call frequency to target physicians, potentially significantly broadening the prescriber base for Auvelity. The increased number of representatives together with our innovative Digital Centric Commercialization (DCC™) platform is expected to increase our reach from approximately 26,000 to approximately 44,000 physicians who write greater than 80% of branded antidepressant prescriptions.
•
Payer coverage for Auvelity across all channels is currently at approximately 68% of all covered lives. The proportion of lives covered in the commercial and government (Medicare and Medicaid) channels are approximately 46% and approximately 100%, respectively. Interactions with payers are ongoing as coverage expansion continues.

 

2

 

 

Sunosi

•
Second quarter 2023 U.S. Sunosi total prescriptions increased by 15% versus the second quarter of 2022, and sequentially by 8% versus the first quarter of 2023.
•
Sunosi maintains broad payer coverage in the commercial channel with 95% of lives covered. Currently 83% of total lives across all channels are covered.

Development Pipeline

Axsome is advancing a portfolio of differentiated, patent-protected, CNS product candidates with five in active clinical development. Recent and anticipated progress for key pipeline programs is summarized below.

AXS-05

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist and sigma-1 agonist being developed for Alzheimer’s disease (AD) agitation and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for AD agitation.

•
Alzheimer’s Disease Agitation: The Company is conducting the ADVANCE-2 study, a Phase 3, placebo-controlled, parallel group trial to assess the efficacy and safety of AXS-05 for the treatment of AD agitation. Patients completing ADVANCE-2 may enter a long-term open label safety extension trial. Based on current enrollment trends, the Company continues to anticipate completion of ADVANCE-2 in the first half of 2024.
•
Smoking Cessation: Axsome plans to proceed to a pivotal Phase 2/3 trial in this indication. The Company anticipates initiation of this study in the fourth quarter of 2023 or the first quarter of 2024.

AXS-07

AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.

•
Migraine: Manufacturing activities related to the planned resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine are progressing. The Company now anticipates resubmission of the NDA in the first half of 2024. No additional clinical efficacy or safety trials have been requested by the FDA for a resubmission of the NDA. The Company expects the NDA resubmission to be designated as Class 2 which would be subject to a six-month review.

AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for the treatment of narcolepsy.

•
Narcolepsy: Axsome is conducting the SYMPHONY study, a Phase 3 randomized, multicenter, double-blind, placebo-controlled, parallel-group trial of AXS-12 in the treatment of narcolepsy. The Company anticipates completion of the SYMPHONY trial in the fourth quarter of 2023.

 

3

 

 

AXS-14

AXS-14 (esreboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

•
Fibromyalgia: Manufacturing and other activities related to the planned submission of an NDA for AXS-14 for the management of fibromyalgia are ongoing. The Company now expects to submit the NDA in the fourth quarter of 2023 or the first quarter of 2024. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the management of fibromyalgia.

Solriamfetol

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist in development for the treatment of attention deficit hyperactivity disorder (ADHD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

•
Attention Deficit Hyperactivity Disorder: In July 2023, Axsome initiated the FOCUS study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. An estimated 11.4 million adults in the U.S. are diagnosed with ADHD, and the condition affects an estimated 5% of children and adolescents.1,2 The disease burden for ADHD is high, with total annual societal excess costs estimated at $122.8 billion for adult ADHD in the U.S.3 The Company anticipates topline results from the FOCUS trial in the second half of 2024.
•
Binge Eating Disorder: Axsome recently received positive pre-IND meeting feedback from the FDA on the development of solriamfetol for the treatment of BED, a potentially new indication for solriamfetol. BED is the most common eating disorder, affecting an estimated 2.8% of U.S. adults.4 Treatment options are limited with only one product currently approved for the treatment of BED. Based on the FDA’s feedback, the Company is preparing to initiate a Phase 3 trial of solriamfetol in patients with BED in the fourth quarter of 2023.
•
Shift Work Disorder: Axsome recently received positive pre-IND meeting feedback from the FDA on the development of solriamfetol for the treatment of excessive sleepiness (ES) associated with SWD, a potentially new indication for solriamfetol. An estimated one third of Americans perform shift work, of whom 10-43% are diagnosed with SWD.5-7 Treatment options are limited with only two products currently approved for the treatment of ES associated with SWD. Based on the FDA’s feedback, the Company is preparing to initiate a Phase 3 trial of solriamfetol in patients with ES associated with SWD in the first quarter of 2024.

Anticipated Milestones

•
Regulatory and Commercial:
o
AXS-07 for migraine, NDA resubmission (1H 2024)
o
AXS-14 for fibromyalgia, NDA submission (4Q 2023 – 1Q 2024)
•
Clinical Trial Readouts:
o
Phase 3 SYMPHONY trial of AXS-12 in narcolepsy (4Q 2023)
o
Phase 3 ADVANCE-2 trial of AXS-05 for Alzheimer’s disease agitation (1H 2024)
o
Phase 3 FOCUS trial of solriamfetol in ADHD in adults (2H 2024)

 

4

 

 

•
Clinical Trial Initiations:
o
Phase 3 trial of solriamfetol for binge eating disorder (4Q 2023)
o
Phase 3 trial of solriamfetol in shift work disorder (1Q 2024)
o
Pivotal Phase 2/3 trial of AXS-05 for smoking cessation (4Q 2023 – 1Q 2024)

Conference Call Information

Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss first quarter 2023 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

 

5

 

 

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi® and Auvelity® products and the success of our efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company’s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

 

 

6

 

 

Axsome Therapeutics, Inc.

Selected Consolidated Financial Data

 

Axsome Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands, except for share and par value amounts)

 

 

 

 

June 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

437,113

 

 

$

200,842

 

Accounts receivables, net

 

 

67,410

 

 

 

37,699

 

Inventories, net

 

 

9,252

 

 

 

4,320

 

Prepaid and other current assets

 

 

5,911

 

 

 

2,781

 

Total current assets

 

 

519,686

 

 

 

245,642

 

Equipment, net

 

 

736

 

 

 

722

 

Right-of-use asset - operating lease

 

 

7,412

 

 

 

420

 

Goodwill

 

 

12,042

 

 

 

10,310

 

Intangible asset, net

 

 

56,500

 

 

 

59,661

 

Non-current inventory and other assets

 

 

15,262

 

 

 

14,721

 

Total assets

 

$

611,638

 

 

$

331,476

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

42,958

 

 

$

38,605

 

Accrued expenses and other current liabilities

 

 

65,324

 

 

 

51,631

 

Operating lease liability, current portion

 

 

350

 

 

 

425

 

Contingent consideration, current

 

 

6,342

 

 

 

5,900

 

Total current liabilities

 

 

114,974

 

 

 

96,561

 

Contingent consideration, non-current

 

 

33,500

 

 

 

31,100

 

Loan payable, long-term

 

 

176,820

 

 

 

94,259

 

Operating lease liability, long-term

 

 

7,540

 

 

 

—

 

Total liabilities

 

 

332,834

 

 

 

221,920

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding at June 30, 2023 and December 31, 2022, respectively)

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value per share (150,000,000 shares authorized, 46,726,794 and 43,498,617 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively)

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

953,520

 

 

 

705,885

 

Accumulated deficit

 

 

(674,721

)

 

 

(596,333

)

Total stockholders’ equity

 

 

278,804

 

 

 

109,556

 

Total liabilities and stockholders’ equity

 

$

611,638

 

 

$

331,476

 

 

7

 

 

 

Axsome Therapeutics, Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

46,017

 

 

$

8,820

 

 

$

74,586

 

 

$

8,820

 

License revenue

 

 

—

 

 

 

—

 

 

 

65,735

 

 

 

—

 

Royalty revenue

 

 

683

 

 

 

—

 

 

 

955

 

 

 

—

 

Total Revenues

 

 

46,700

 

 

 

8,820

 

 

 

141,276

 

 

 

8,820

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (excluding amortization and depreciation)

 

 

4,599

 

 

 

983

 

 

 

12,155

 

 

 

983

 

Research and development

 

 

20,581

 

 

 

15,792

 

 

 

38,374

 

 

 

28,377

 

Selling, general and administrative

 

 

78,935

 

 

 

31,160

 

 

 

153,126

 

 

 

56,864

 

Loss (Gain) in fair value of contingent consideration

 

 

6,053

 

 

 

(860

)

 

 

5,891

 

 

 

(860

)

Intangible asset amortization

 

 

1,589

 

 

 

926

 

 

 

3,161

 

 

 

926

 

Total operating expenses

 

 

111,757

 

 

 

48,001

 

 

 

212,707

 

 

 

86,290

 

Loss from operations

 

 

(65,057

)

 

 

(39,181

)

 

 

(71,431

)

 

 

(77,470

)

Interest expense, net

 

 

(2,730

)

 

 

(2,257

)

 

 

(4,994

)

 

 

(3,601

)

Loss before income taxes

 

 

(67,787

)

 

 

(41,438

)

 

 

(76,425

)

 

 

(81,071

)

Income tax benefit (expense)

 

 

617

 

 

 

—

 

 

 

(1,963

)

 

 

—

 

Net loss

 

$

(67,170

)

 

$

(41,438

)

 

$

(78,388

)

 

$

(81,071

)

Net loss per common share, basic and diluted

 

$

(1.54

)

 

$

(1.06

)

 

$

(1.80

)

 

$

(2.09

)

Weighted average common shares outstanding, basic and diluted

 

 

43,669,820

 

 

 

39,081,100

 

 

 

43,597,131

 

 

 

38,704,227

 

 

Axsome Contacts:

Investors:

Mark Jacobson

Chief Operating Officer

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 212-332-3243

Email: mjacobson@axsome.com

www.axsome.com

 

Media:

Darren Opland

Director, Corporate Communications

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 929-837-1065

Email: dopland@axsome.com

www.axsome.com

 

 

8

 

 

References:

1.
Faraone, S., Asherson, P., Banaschewski, T. et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 1, 15020 (2015). https://doi.org/10.1038/nrdp.2015.20
2.
Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006 Apr;163(4):716-23. doi: 10.1176/ajp.2006.163.4.716
3.
Schein J, et al. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. JMCP. 2022. 28:2, 168-179. doi: 10.18553/jmcp.2021.21290
4.
J. I. Hudson, E. Hiripi, H. G. Pope, and R. C. Kessler, “The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication,” Biol. Psychiatry, vol. 61, no. 3, pp. 348–358, Feb. 2007, doi: 10.1016/j.biopsych.2006.03.040.
5.
Alterman, T., Luckhaupt, S. E., Dahlhamer, J. M., Ward, B. W. & Calvert, G. M. Prevalence rates of work organization characteristics among workers in the U.S.: data from the 2010 National Health Interview Survey. Am. J. Ind. Med. 56, 647–659 (2013).
6.
Drake, C. L., Roehrs, T., Richardson, G., Walsh, J. K. & Roth, T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 27, 1453–1462 (2004).
7.
Wickwire, E. M., Geiger-Brown, J., Scharf, S. M. & Drake, C. L. Shift Work and Shift Work Sleep Disorder: Clinical and Organizational Perspectives. Chest 151, 1156–1172 (2017).

 

9

 

 GRAPHIC 3 img36028404_0.jpg GRAPHIC begin 644 img36028404_0.jpg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end EX-101.LAB 4 axsm-20230807_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 5 axsm-20230807.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 6 axsm-20230807_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2023
Entity Registrant Name Axsome Therapeutics, Inc.
Entity Central Index Key 0001579428
Entity Emerging Growth Company false
Securities Act File Number 001-37635
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4241907
Entity Address, Address Line One One World Trade Center, 22nd Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10007
City Area Code (212)
Local Phone Number 332-3241
Entity Information, Former Legal or Registered Name Axsome Therapeutics, Inc.
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol AXSM
Security Exchange Name NASDAQ
XML 8 axsm-20230807_htm.xml IDEA: XBRL DOCUMENT 0001579428 2023-08-07 2023-08-07 0001579428 false 8-K 2023-08-07 Axsome Therapeutics, Inc. DE 001-37635 45-4241907 One World Trade Center, 22nd Floor New York NY 10007 (212) 332-3241 Axsome Therapeutics, Inc. false false false false Common Stock, Par Value $0.0001 Per Share AXSM NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports axsm-20230807.htm axsm-20230807.xsd axsm-20230807_lab.xml axsm-20230807_pre.xml axsm-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axsm-20230807.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "axsm-20230807.htm" ] }, "labelLink": { "local": [ "axsm-20230807_lab.xml" ] }, "presentationLink": { "local": [ "axsm-20230807_pre.xml" ] }, "schema": { "local": [ "axsm-20230807.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "axsm", "nsuri": "http://axsome.com/20230807", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "axsm-20230807.htm", "contextRef": "C_bbe9c9a2-c612-4ad2-8fab-03189464a928", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "axsm-20230807.htm", "contextRef": "C_bbe9c9a2-c612-4ad2-8fab-03189464a928", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axsome.com/20230807/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-039035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-039035-xbrl.zip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end